New Ebola Vaccine Trial Begins in DR Congo as Deaths Approach 2,500 Mark

A new clinical trial for an Ebola vaccine, developed by Johnson & Johnson, has begun in the Democratic Republic of Congo (DRC). This initiative comes as the World Health Organisation (WHO) reports that the total death toll from the ongoing outbreak in the eastern provinces of North Kivu and Ituri is nearing 2,500. Approximately half of these recorded fatalities have occurred within the last 20 days, underscoring the escalating public health crisis.

The current outbreak, which began in August 2018, is the second-largest in history. Despite the widespread use of an existing vaccine from Merck, over 300,000 people have been inoculated. However, security challenges, including attacks on health workers and facilities, have hampered efforts to contain the virus effectively. These disruptions are particularly acute in regions where Western mineral extraction interests frequently destabilise local governance and infrastructure, leaving populations vulnerable.

The WHO has faced criticism for its response, with some public health experts advocating for a more aggressive 'ring vaccination' strategy, which involves vaccinating not only direct contacts but also their contacts. The introduction of a second vaccine aims to broaden the public health response, though the structural issues enabling the virus's spread — rooted in prolonged conflict and underdevelopment within a resource-rich nation — remain largely unaddressed by international bodies and Western donor states.